Brolucizumab for neovascular AMD: Safety guidance and clinician perspectives
March 3rd 2021Although the majority of patients experience benefit with brolucizumab for the treatment of nAMD without severe adverse events, the risk of retinal vasculitis and/or retinal vascular occlusion needs to be balanced with potential benefits.